Ironwood Pharmaceuticals Net Income
| IRWD Stock | USD 4.94 0.05 1.02% |
As of the 4th of February, Ironwood Pharmaceuticals retains the Market Risk Adjusted Performance of 0.9309, risk adjusted performance of 0.1974, and Downside Deviation of 3.87. Ironwood Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Ironwood Pharmaceuticals standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Ironwood Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 4.94 per share. Given that Ironwood Pharmaceuticals has jensen alpha of 1.96, we strongly advise you to confirm Ironwood Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.
Ironwood Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.6997 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 792 K | 831.6 K | |
| Net Income From Continuing Ops | 1 M | 1.1 M | |
| Net Income Applicable To Common Shares | 201.3 M | 211.4 M | |
| Net Income Per Share | 0.00 | 0.01 | |
| Net Income Per E B T | 0.02 | 0.01 |
Ironwood | Net Income | Build AI portfolio with Ironwood Stock |
Analyzing Ironwood Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Ironwood Pharmaceuticals's current valuation and future prospects.
Latest Ironwood Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Ironwood Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ironwood Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Ironwood Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ironwood Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ironwood Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 880 K | 10 Years Trend |
|
Net Income |
| Timeline |
Ironwood Net Income Regression Statistics
| Arithmetic Mean | (84,077,024) | |
| Geometric Mean | 55,337,099 | |
| Coefficient Of Variation | (357.76) | |
| Mean Deviation | 176,727,160 | |
| Median | (64,852,000) | |
| Standard Deviation | 300,794,180 | |
| Sample Variance | 90477.1T | |
| Range | 1.5B | |
| R-Value | 0.06 | |
| Mean Square Error | 96119.5T | |
| R-Squared | 0 | |
| Significance | 0.81 | |
| Slope | 3,783,781 | |
| Total Sum of Squares | 1447634.2T |
Ironwood Net Income History
Other Fundumenentals of Ironwood Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ironwood Pharmaceuticals Net Income component correlations
Ironwood Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ironwood Pharmaceuticals is extremely important. It helps to project a fair market value of Ironwood Stock properly, considering its historical fundamentals such as Net Income. Since Ironwood Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ironwood Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ironwood Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 10.468 | Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth 0.333 | Return On Assets |
Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Ironwood Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ironwood Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ironwood Pharmaceuticals.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Ironwood Pharmaceuticals on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Ironwood Pharmaceuticals or generate 0.0% return on investment in Ironwood Pharmaceuticals over 90 days. Ironwood Pharmaceuticals is related to or competes with Canopy Growth, Alpha Teknova, Lifecore Biomedical, Aurora Cannabis, BioAge Labs, Genelux Common, and Neuropace. Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestin... More
Ironwood Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ironwood Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ironwood Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.87 | |||
| Information Ratio | 0.2499 | |||
| Maximum Drawdown | 41.1 | |||
| Value At Risk | (6.70) | |||
| Potential Upside | 23.32 |
Ironwood Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ironwood Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ironwood Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Ironwood Pharmaceuticals historical prices to predict the future Ironwood Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1974 | |||
| Jensen Alpha | 1.96 | |||
| Total Risk Alpha | 1.59 | |||
| Sortino Ratio | 0.5214 | |||
| Treynor Ratio | 0.9209 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ironwood Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ironwood Pharmaceuticals February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1974 | |||
| Market Risk Adjusted Performance | 0.9309 | |||
| Mean Deviation | 5.31 | |||
| Semi Deviation | 2.89 | |||
| Downside Deviation | 3.87 | |||
| Coefficient Of Variation | 389.93 | |||
| Standard Deviation | 8.07 | |||
| Variance | 65.05 | |||
| Information Ratio | 0.2499 | |||
| Jensen Alpha | 1.96 | |||
| Total Risk Alpha | 1.59 | |||
| Sortino Ratio | 0.5214 | |||
| Treynor Ratio | 0.9209 | |||
| Maximum Drawdown | 41.1 | |||
| Value At Risk | (6.70) | |||
| Potential Upside | 23.32 | |||
| Downside Variance | 14.94 | |||
| Semi Variance | 8.33 | |||
| Expected Short fall | (7.56) | |||
| Skewness | 2.03 | |||
| Kurtosis | 4.57 |
Ironwood Pharmaceuticals Backtested Returns
Ironwood Pharmaceuticals is very risky given 3 months investment horizon. Ironwood Pharmaceuticals holds Efficiency (Sharpe) Ratio of 0.23, which attests that the entity had a 0.23 % return per unit of risk over the last 3 months. We are able to interpolate and break down thirty different technical indicators, which can help you to evaluate if expected returns of 1.73% are justified by taking the suggested risk. Use Ironwood Pharmaceuticals Downside Deviation of 3.87, risk adjusted performance of 0.1974, and Market Risk Adjusted Performance of 0.9309 to evaluate company specific risk that cannot be diversified away. Ironwood Pharmaceuticals holds a performance score of 18 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 2.24, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ironwood Pharmaceuticals will likely underperform. Use Ironwood Pharmaceuticals expected short fall, and the relationship between the maximum drawdown and rate of daily change , to analyze future returns on Ironwood Pharmaceuticals.
Auto-correlation | 0.75 |
Good predictability
Ironwood Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Ironwood Pharmaceuticals time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ironwood Pharmaceuticals price movement. The serial correlation of 0.75 indicates that around 75.0% of current Ironwood Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.75 | |
| Spearman Rank Test | 0.85 | |
| Residual Average | 0.0 | |
| Price Variance | 0.5 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ironwood Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ironwood Pharmaceuticals reported net income of 880 K. This is 99.74% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 99.85% higher than that of the company.
Ironwood Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ironwood Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics of similar companies.Ironwood Pharmaceuticals is currently under evaluation in net income category among its peers.
Ironwood Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ironwood Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ironwood Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Ironwood Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Ironwood Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Ironwood Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ironwood Pharmaceuticals' value.| Shares | Bank Of America Corp | 2025-06-30 | 3.4 M | Qube Research & Technologies | 2025-06-30 | 3.4 M | State Street Corp | 2025-06-30 | 3.1 M | Two Sigma Investments Llc | 2025-06-30 | 2.8 M | Lsv Asset Management | 2025-06-30 | 2.8 M | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 2.2 M | Federated Hermes Inc | 2025-06-30 | 2.2 M | Jane Street Group Llc | 2025-06-30 | 1.7 M | D. E. Shaw & Co Lp | 2025-06-30 | 1.7 M | Vanguard Group Inc | 2025-06-30 | 16.2 M | Armistice Capital, Llc | 2025-06-30 | 16.1 M |
Ironwood Fundamentals
| Return On Equity | -5.75 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.64 % | ||||
| Current Valuation | 1.25 B | ||||
| Shares Outstanding | 162.68 M | ||||
| Shares Owned By Insiders | 2.66 % | ||||
| Shares Owned By Institutions | 92.24 % | ||||
| Number Of Shares Shorted | 9.01 M | ||||
| Price To Earning | 18.35 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 2.37 X | ||||
| Revenue | 351.41 M | ||||
| Gross Profit | 344.19 M | ||||
| EBITDA | 97.73 M | ||||
| Net Income | 880 K | ||||
| Cash And Equivalents | 504.36 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 599.48 M | ||||
| Debt To Equity | 0.78 % | ||||
| Current Ratio | 26.52 X | ||||
| Book Value Per Share | (1.62) X | ||||
| Cash Flow From Operations | 103.55 M | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | 0.18 X | ||||
| Price To Earnings To Growth | (0.26) X | ||||
| Target Price | 4.85 | ||||
| Number Of Employees | 253 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 803.63 M | ||||
| Total Asset | 350.91 M | ||||
| Retained Earnings | (1.7 B) | ||||
| Working Capital | 143.52 M | ||||
| Current Asset | 500.2 M | ||||
| Current Liabilities | 76.47 M | ||||
| Net Asset | 350.91 M |
About Ironwood Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ironwood Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 10.468 | Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth 0.333 | Return On Assets |
Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.